West Cancer Center

BREAST; METASTATIC: PHASE 1 (EXPANSION): TRIPLE NEGATIVE: 1st Line: MORPHEUS

A Phase 1b/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer

Title

Genentech CO40115 (MORPHEUS-Breast)

Study Title

Site Link

NCT03424005

Malignancy

Breast, Triple Negative Breast Cancer, TNBC

Stage

Stage 4

Disease Setting

Metastatic/Palliative

Line Of Therapy

2nd Line

Investigational Agent

Atezolizumab with Ipatasertib or ladiratuzumab-vidotin or Bevacizumab or Cobimetinib or Capecitabine or Combination Chemo

Drug Class

PD-L1 antibody with either PI3Ki or LIV1A ADC or MEKi or VEGFRi or chemo

Greg Vidal, MD, PhD

Sponsor

Hoffman-La Roche

Phase

Phase 1

Status

Open to Enrollment

Key Eligibility Criteria

Key Eligibility Criteria Details

Triple negative metastatic breast cancer
2nd line
ECOG PS 0-2
No prior treatment with any study agents
No history of autoimmune disease
Presence of measurable disease
No symptomatic or untreated CNS disease

Objective

Primary- ORR; Secondary- PFS, DCR, OS, DoR, safety, PK

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

ER- (negative), PR- (negative), HER2- (negative)

Dosing Frequency

Control Agents

Study Protocol

Randomized

Yes